Is it cost-effective to use genetic tools to predict how well patients with cystic fibrosis will respond to treatment?
How the discovery of new white blood cell subtypes can improve our understanding of lung disease progression in adult CF patients?
Two-year follow-up results from an ongoing study on the safety and effectiveness of elexacaftor/tezacaftor/ivacaftor when used in real-world settings by people with cystic fibrosis
Children and Adolescents with CF who have a patchy liver on a research ultrasound (US) are at increased risk of developing advanced CF liver disease
Impact of the De-escalation of Supportive Therapies in Patients with Cystic Fibrosis Taking Elexacaftor, Tezacaftor, Ivacaftor
Autoimmunity (a condition where the body's immune system mistakes its own healthy tissues as foreign and attacks them) in People with Cystic Fibrosis
